Results 9,261-9,280 of 13,038 for speaker:Louise O'Reilly
- Written Answers — Department of Finance: Insurance Industry (22 Nov 2018)
Louise O'Reilly: 20. To ask the Minister for Finance the steps he will take to ensure that residents affected by the liquidation of the structural warranty of an underwriter (details supplied) are not unfairly affected; and his plans to deal with this issue. [48604/18]
- Written Answers — Department of Health: Patient Safety (22 Nov 2018)
Louise O'Reilly: 150. To ask the Minister for Health if his attention has been drawn to the fact that a patient with tuberculosis was not isolated while at University Hospital Galway; and if disclosures of this incident have been made to him. [48774/18]
- Older People: Motion [Private Members] (21 Nov 2018)
Louise O'Reilly: Home supports, home help packages and home help hours are some of the most vital services provided by the State. This was evident to me as someone who represented home help workers a number of years ago when the Fianna Fáil-led Government brought in the moratorium on recruitment. As bad as things were, home help workers were exempted because it was a good value for money service....
- Ceisteanna Eile - Other Questions: Defence Forces Recruitment (21 Nov 2018)
Louise O'Reilly: 71. To ask the Taoiseach and Minister for Defence the steps being taken to address the retention crisis in the Defence Forces; when the target staffing level of the Defence Forces will be met; and if he will make a statement on the matter. [47797/18]
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I thank the witnesses for coming in this morning. We have talked a little about bringing transparency into the process but we keep coming up against the barrier of commercial sensitivity. Is there any country that does it better? Could we look to Scotland or replicate what is being done in any other country? Do we need to reinvent the wheel if another country has gone to the trouble of...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: The challenge is to bring the voices in and to recognise that when the answer is "No" it is because the drug is not going to work and not because the system is just giving a blanket "No". Patients feel they are not involved in the process.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I did not mention any company but it was high-profile-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: It looked like a map of an underground from somewhere.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: It was very convoluted.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: Mr. Watt said he observed one of the PACE meetings in Scotland. Would it be fair to say be advocates were there on an equal footing and their contribution was-----
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: There is probably more said by what is left out than what is in the public domain.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I thank the witnesses for being here. We respect and appreciate the job the witnesses do and we acknowledge that very often they are portrayed as the bad guys but sometimes they do not help their own cause. Patients come to us because they want to know the status of their approvals. They should not have to contact their local public representatives to get that information. It should be...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: My question was about moving along through the process.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: The NCPE is not the only organisation involved.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I acknowledge that but the witnesses are collectively representing the Department and the HSE. The progress is being tracked through all committees.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: In order to make a submission, patients submit an online form rather than participate in a one-to-one meeting.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: Do the witnesses accept that there is a problem with the current system? Do they accept that notwithstanding the work that has been done to bring families into the process to some degree, the families are still experiencing difficulty with the process and their level of involvement in it? I am not saying that the people in this room do not work hard; I fully appreciate that they do....
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I asked the question of all the witnesses. I have not taken much time.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: With regard to the point------
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Louise O'Reilly: I ask the Chair to allow me to finish as Mr. Flanagan's reply was not particularly fair.